我们中心旨在阐明难治/复发儿童白血病的发病机制，建立儿童造血衰竭疾病标准化诊疗体系，为罕见儿童血液病建立造血干细胞移植模式，尤其是非血缘脐血干细胞的移植模式。
近几年，我们对儿童造血系统恶性增殖性疾病进行了深入研究并取得优异成果。通过对同卵双胞胎发生白血病的研究我们挖掘出新的抑癌基因SETD2，进而揭示HSC恶变的表观调控新机制，为白血病提供新的分子标志和干预靶点。通过对难治/复发儿童急性淋巴细胞白血病的研究，我们发现ph-like急性淋巴细胞白血病发生耐药的克隆演变规律。此外，我们也非常关注儿童造血衰竭性疾病这一类良性血液病。先天性造血衰竭疾病涉及了DNA损伤修复、核糖体蛋白基因突变、端粒酶基因突变等多个管家基因途径；基于范科尼贫血（FA）的临床研究我们发现同一FA患者可同时携带多个FA致病基因，然而其在FA发生发展中的作用机制尚不明确。这些研究使我们认识到儿童血液病尚存很多未解问题，我们将继续对各种儿童血液病队列研究中发现的问题进行不断探索，以解决临床上未解之问题。
我们实验室欢迎有兴趣的科学家加入到我们的队伍，来共同探索儿童白血病克隆演变的机制、儿童造血衰竭疾病的发生机制及治疗策略。
1992 日本北海道大学 博士
1981 白求恩医科大学 学士
至今 - 2005.11 中国医学科学院血液病医院血液儿科 主任医师 主任
2005.10~1999.11 中国医学科学院血液病医院血液儿科 副主任医师，主任
1999.10~1998.11 中国医学科学院血液病医院血液儿科 主任
1998.10~1994.10 中国医学科学院血液病医院血液内科 主治医师
1994.09~1992.09 日本北海道大学医学部 研修
1992.08~1986.07 中国医学科学院血液病医院血液内科住院医师和住院总医师
1. National Natural Science Foundation of China, NSFC. No.81870131
Title:The study of clonal evolution and relapse of pediatric B cell acute lymphoblastic leukemia via single-cell sequencing technology.
Role：PI.（2019-2022）
Amount of subsidy：RMB 600,000.00
2. National Natural Science Foundation of China, NSFC（International cooperation project）. No.82011530198
Title: Mechanisms of bone marrow failure and leukaemogenesis in human ribosomopathies
Amount of subsidy：RMB 100,000.00
Role: PI（2020-2022）
3. National Natural Science Foundation of China, NSFC. No.81670112
Title: The functional study of Glucocorticoid receptor signaling pathway in pathogenesis and treatment of Diamond Blackfan Anemia
Amount of subsidy：RMB 600,000.00
Role: PI（2017-2020）
4. National Natural Science Foundation of China, NSFC. No.81470339
Title:The mRNA methylation-mediated regulation of childhood acute lymphoblastic leukemia caused by TEL/AML1 gene fusion mutaion
Amount of subsidy：RMB 700,000.00
Role: PI（2015-2018）
5. National Natural Science Foundation of China, NSFC. No.81170470
Title:To dissect molecular mechanisms of Fanconi anemia
Amount of subsidy：RMB 600,000.00
Role: PI（2012-2015）
1. Shen S, Chen X, Cai J, et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial [published online ahead of print, 2020 Jan 16]. JAMA Oncol. 2020;6(3):358-366.
2. Zhang A, Chen X, Li Z, et al. Acute myeloid leukemia arising after Hodgkin lymphoma in a patient with WHIM syndrome. Pediatr Blood Cancer. 2019 Nov; 66(11):e27951.
3. Liu LP, Chen XJ, Yang WY, et al. Predicting response to porcine antilymphocyte globulin plus cyclosporine A in children with acquired severe aplastic anemia, Pediatr Res. 2019 May 21. doi: 10.1038/s41390-019-0437-1.
4. Atsushi Narita, Xiaofan Zhu, Hideki Muramatsu, et al. Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia.BJH, 2019, 187, 227–237
5. Chen X, Ying Wang, Min Ruan, et al. Treatment of testicular relapse of B-cell acute lymphoblastic leukemia with CD19-specific chimeric antigen receptor T cells. 2019. CLML 1458.
6. Zhang A, Chen X, Li Z, et al. Acute myeloid leukemia arising after Hodgkin lymphoma in a patient with WHIM syndrome. Pediatr Blood Cancer. 2019 Nov; 66(11):e27951.
7. Zhang J*, Zhang Y*, Zhang M, et al. FLT3 pathway is a potential therapeutic target for PRC2 mutated T cell acute lymphoblastic leukemia. Blood. 2018 Oct 3. pii: blood-2018-04-845628.
8. Bacigalupo A, Oneto R, Schrezenmeier H, et al. First line treatment of aplastic anemia with thymoglobuline in europe and asia: Outcome of 955 patients treated 2001-2012. Am J Hematol. 2018 Mar 2. doi: 10.1002/ajh.25081. [Epub ahead of print]
9. Yingchi Zhang, Yufeng Gao, Hui Zhang, et al. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood. 2018 Feb 6. pii: blood-2017-11-817510. doi: 10.1182/blood-2017-11-817510. [Epub ahead of print]
10. Zhan D, Zhang Y, Xiao P, et al. Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia.Leuk Res. 2018 Feb;65:20-24. doi: 10.1016/j.leukres.2017.12.001. Epub 2017 Dec 8.
11. Zhang Y, Zhang J, An W, et al. Intron 1 GATA site enhances ALAS2 expression indispensably during erythroid differentiation. Nucleic Acids Res. 2017; 25;45(2):657-671. doi: 10.1093.
12. Sun C, Chang L, Zhu X. Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse. Oncotarget. 2017 May 23;8(21):35445-35459. doi: 10.18632/oncotarget.16367. Review
13. Wan Y, Chen X, An W, et al. Clinical features, mutations and treatment of 104 patients of Diamond-Blackfan anemia in China: a single-center retrospective study. Int J Hematol. 2016 Oct;104(4):430-9. doi: 10.1007/s12185-016-2044-9. Epub 2016 Jun 21.
14. Wei W, Chen X, Zou Y, et al. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China. BMC Pediatr. 2015; 15:80.DOI 10.1186/s12887-015-0390-z
15. Zhang Y, Peng L, Hu T, et al. La-related protein 4B maintains murine MLL-AF9 leukemia stem cell self-renewal by regulating cell cycle progression. Exp Hematol. 2015;43(4):309-18
津公网安备12010102000385号